Published online 14 January 2009
Haematologica, Vol 94, Issue 2, 239-248 doi:10.3324/haematol.13356
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stussi, G.
Right arrow Articles by Seebach, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stussi, G.
Right arrow Articles by Seebach, J. D.

Stem Cell Transplantation

Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins

Georg Stussi1, Jörg Halter2, Eveline Bucheli1, Piero V. Valli1, Lutz Seebach1, Jürg Gmür3, Alois Gratwohl2, Urs Schanz1, Jakob R. Passweg4, Jörg D. Seebach1,5

1 Clinic for Hematology and Laboratory for Transplantation Immunology, Department of Internal Medicine, University Hospital, Zürich
2 Division of Hematology, Department of Internal Medicine, University Hospital Basel
3 Onkozentrum, Klinik im Park, Zürich
4 Services of Hematology and
5 mmunology and Allergology, I Department of Internal Medicine, University Hospital and Medical Faculty, Geneva, Switzerland

Correspondence: Georg Stussi, University, Hospital Zurich, Department, of Internal Medicine, Clinic for, Hematology, Rämistrasse 100, CH-8091 Zurich, Switzerland., Email:georg.stuessi{at}usz.ch

Background: Persistent anti-donor isoagglutinins after major ABO blood group incompatible hematopoietic stem cell transplantation may cause delayed red blood cell engraftment and post-transplant pure red cell aplasia.

Design and Methods: We investigated the effect of pretransplant anti-donor isoagglutinin reduction by in vivo absorption and/or plasmapheresis on the incidence of pure red cell aplasia and the time to red blood cell engraftment in 153 hematopoietic stem cell transplant recipients with major ABO incompatibility.

Results: Twelve patients (8%) developed pure red cell aplasia, 3/98 (3%) with, and 9/55 (16%) without prior isoagglutinin reduction (p=0.009). Red blood cell engraftment was faster in patients with isoagglutinin reduction; in addition, peripheral blood hematopoietic stem cell transplantation, acute graft-versus-host disease, and younger age were associated with faster red blood cell engraftment in Cox regression analysis. In patients with pure red cell aplasia the mean red blood cell engraftment occurred after 225 days (p<0.001) and was associated with a simultaneous decrease of anti-donor isoagglutinins. Patients with pure red cell aplasia had higher pretransplant anti-donor isoagglutinin titers (p=0.001) and received more post-transplant red blood cell transfusions (p<0.001).

Conclusions: Following major ABO incompatible hematopoietic stem cell transplantation, pure red cell aplasia and delayed red blood cell engraftment depend on the levels of anti-donor isoagglutinins and are efficiently prevented by the pretransplant removal of these isoagglutinins. The benefits of reducing the time of transfusion-dependency and transfusion-associated risks must be carefully balanced against the potential side effects of isoagglutinin reduction.

Key words: ABO blood group incompatibility, allogeneic hematopoietic stem cell transplantation, pure red cell aplasia.